Fresenius Medical Care AG & Co. KGaA (FMS) Projected to Release Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) will likely be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.6510 per share and revenue of $5.54 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.48 billion. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2.24 EPS for the current fiscal year and $2.31 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.3%

Shares of NYSE FMS opened at $22.75 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $20.02 and a 52-week high of $27.40. The firm has a fifty day moving average of $22.48 and a 200-day moving average of $22.89. The stock has a market capitalization of $12.22 billion, a PE ratio of 11.78, a P/E/G ratio of 5.29 and a beta of 0.74. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

FMS has been the topic of several research reports. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 target price on the stock. in a research report on Tuesday, July 28th. Berenberg Bank set a $24.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 15th. Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Truist Financial cut their price objective on Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating on the stock in a report on Monday, October 12th. Seven investment analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $23.42.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.